The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
Abstract
The efficacy and tolerability of Lu AA21004 in the prevention of relapse of major depressive disorder (MDD) in patients in remission after acute treatment was evaluated. Patients ( n=639) aged 18–75 years with a primary diagnosis of MDD with a current major depressive episode (MDE) ≥4 weeks’ duration, at least one prior MDE and a MADRS total score ≥26 received 12-week, open-label Lu AA21004 at 5 or 10mg/day. Patients in remission (MADRS ≤10) at both weeks 10 and 12 were assigned to double-blind treatment with either placebo or Lu AA21004 (fixed dose from Week 8).Patients (n=396) were treated, after random assignment to placebo (n=192) or Lu AA21004 (n=204). The primary analysis of time to relapse (full-analysis set, Cox proportional hazard model) showed a statistically significant difference in favour of Lu AA21004 versus placebo with a hazard ratio of 2.01 (95% confidence interval: 1.26–3.21; p=0.0035). The proportion of patients who relapsed was 13% in the Lu AA21004 group ( n=27) and 26% in the placebo group ( n=50). The withdrawal rates due to adverse events were 8% (open-label), and 3% (placebo) and 8% (Lu AA21004) (double-blind). Thus, Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the relapse rates observed in the current study were similar to those reported in recently completed studies with desvenlafaxine versus placebo (13.6% vs. 28.3%; Rosenthal, Boyer, Vialet, Hwang, & Tourian, 2013) and vortioxetine versus placebo (13% vs. 26%; Boulenger, Loft, & Florea, 2012).”
From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Boulenger, Loft, & Florea, 2012
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 2×
“When compared with the results of a meta-analysis based on seven clinical trials using a relapse-prevention design with placebo substitution after a one to two month open-label antidepressant treatment of MDD followed by a six-month relapse prevention period (Geddes et al., 2003), our results appear to be similar for…”
BackgroundResultBang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.469 · Cited by 382
Research works printed but not linked: 2
- Adell A, 2010, Drugs, 13, 900
- Mørk A, 2011, Biol Psychiatry, 69, 186S
Cited by
Sorted by citations
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 663
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang‐Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 247
Metadata
- Authors
- Boulenger, J.-P., Loft, H., & Florea, I.
- Affiliations
- Université Montpellier 1 (FR)
- Lundbeck (Denmark) (DK)
- ORCID
- Florea, Ioana
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-04-09
- Volume
- 26
- Issue
- 11
- Pages
- 1408-1416
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2066283885
- Semantic Scholar
- 09b9fc5799e896bbdda5703b74a14db0438fa09a
- Cited by
- 127
- References
- 22
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 2 · 2017: 10 · 2016: 12 · 2015: 25 · 2014: 18 · 2013: 7 · 2012: 5
- FWCI
- 12.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- vortioxetine, major depressive disorder, relapse prevention, maintenance therapy, antidepressant efficacy, drug tolerability, time to relapse, remission, adverse events
- MeSH terms
- Vortioxetine, Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Piperazines, Sulfides, Proportional Hazards Models, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
